Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Hodgkin Disease 65 Lymphoma 39 Urinary Bladder Neoplasms 16 Carcinoma, Non-Small-Cell Lung 11 Melanoma 9 Lung Neoplasms 9 Urethral Neoplasms 4 Recurrence 4 Prostatic Neoplasms 4 Lymphoma, Large-Cell, Anaplastic 4 Testicular Neoplasms 3 Neoplasms 3 Leukemia 3 Glioma 3 Central Nervous System Neoplasms 3 Astrocytoma 3 Testicular Germ Cell Tumor 2 Teratoma 2 Skin Neoplasms 2 Oligodendroglioma 2 Neurofibromatosis 1 2 Kidney Neoplasms 2 HIV Infections 2 Carcinoma, Renal Cell 2 Breast Neoplasms 2 Brain Neoplasms 2 Uterine Cervical Neoplasms 1 Urothelial Carcinoma of the Bladder 1 Ureteral Neoplasms 1 Survival Without Progression 1

Interventions

Rituximab 416 Cyclophosphamide 348 Vincristine 173 Prednisone 172 Doxorubicin 168 Etoposide 160 Peripheral Blood Stem Cell Transplantation 114 Filgrastim 108 Lenalidomide 97 fludarabine phosphate 96 Radiotherapy 80 Cytarabine 80 Gemcitabine 73 Melphalan 66 Mycophenolic Acid 64 Cyclosporine 60 Methotrexate 59 Busulfan 57 Ifosfamide 55 Carmustine 55 fludarabine 50 Tacrolimus 50 Whole-Body Irradiation 49 Carboplatin 49 polatuzumab vedotin 44 Oxaliplatin 44 Dexamethasone 44 Antilymphocyte Serum 42 ibrutinib 40 Bendamustine Hydrochloride 40

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Lymphoma, Large B-Cell, Diffuse × Vinblastine × Clear all

NCT01148446 2010-06-22

ANZINTER3

Fondazione Italiana Linfomi - ETS

Phase 3 Completed

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon ⚡